Varol, BasakCoskun, OzlemKarabulut, SenemSerin, Kursat RahmiAsoglu, OktarAlbeniz, IsilTas, Faruk2025-01-272025-01-2720141010-42831423-0380https://doi.org/10.1007/s13277-014-1735-1https://hdl.handle.net/20.500.12428/22732The objective of this study was to evaluate the clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer (CRC). A total of 108 patients with CRC who underwent curative surgery and 20 healthy volunteers were enrolled in this study. ADP-ribosylation and NAD glycohydrolase activity levels were determined. The association of ADP-ribosylation and NAD glycohydrolase with clinical and laboratory factors and their impact on overall survival (OS) and disease free survival (DFS) were shown. The preoperative ADP-ribosylation and NAD glycohydrolase activity levels were significantly higher in patients with CRC than in the control group (p < 0.001). ADP-ribosylation and NAD glycohydrolase activity levels were correlated with tumor stage (p = 0.05, p = 0.001), stage of disease (p < 0.001, p < 0.001), serum CEA level (p < 0.001, p < 0.001), and site of lesion (p < 0.001, p < 0.001), respectively. Patients with high ADP-ribosylation had significantly unfavorable OS and DFS compared with those with lower levels (p < 0.001, p < 0.001), respectively. Moreover, the patients with high NAD glycohydrolase activity showed significantly worse OS and DFS rates, similar to ADP-ribosylation. Serum levels of ADP-ribosylation and NAD glycohydrolase activity correlate well with tumor stage, stage of disease, serum CEA level, and site of lesion. In conclusion, elevated levels of preoperative ADP-ribosylation and NAD glycohydrolase levels in serum are associated with poor prognosis in patients with CRC.eninfo:eu-repo/semantics/closedAccessColorectal cancerADP-ribosylationNAD glycohydrolase activitySerumArticle3565575558210.1007/s13277-014-1735-1Q2WOS:0003370949000662-s2.0-8490472117324535779Q3